Patents Issued in April 28, 2020
-
Patent number: 10633390Abstract: The present invention relates to an improved process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester compound of formula-1 represented by the following structural formula:Type: GrantFiled: June 27, 2016Date of Patent: April 28, 2020Assignee: MSN LABORATORIES PRIVATE LIMITEDInventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Revu Satyanarayana
-
Diol, method for manufacturing diol, di(meth)acrylate, and method for manufacturing di(meth)acrylate
Patent number: 10633391Abstract: Provided is a diol that excels in thermal stability; and, a method for manufacturing a diol, a di(meth)acrylate, and a method for manufacturing a di(meth)acrylate. The diol represented by the formula (1) below; wherein each of R1 and R2 independently represents a hydrocarbon group; and each R3 independently represents a hydrogen atom, hetero atom-containing group, halogen atom, straight chain alkyl group having 1 to 6 carbon atoms, branched alkyl group having 3 to 6 carbon atoms or, aryl group-containing group having 6 to 12 carbon atoms.Type: GrantFiled: October 11, 2017Date of Patent: April 28, 2020Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventors: Hideyuki Sato, Atsushi Okamoto, Taketo Ikeno, Tetsuya Shimo -
Patent number: 10633392Abstract: The present invention provides unified synthesis of the CI-CI 9 building blocks of halichondrins and analogs thereof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present invention also provides a practical and efficient synthesis of C20-C38 building blocks of halichondrins and analogs thereof. Also provided herein are general methods of selective activation and coupling of poly-halogenated analogs with an aldehyde. The provided coupling reactions are selective for halo-enone and halo-acetylenic ketal over vinyl halide and halide attached to a sp hydridized carbon. The provided efficient selective coupling reactions can allow easy access to the CI-CI 9 building blocks and C20-C38 building blocks of halichondrins and analogs thereof with limited or no purification or separation of the intermediates.Type: GrantFiled: June 14, 2019Date of Patent: April 28, 2020Assignee: President and Fellows of Harvard CollegeInventors: Yoshito Kishi, Wuming Yan, Jingwei Li, Zhanjie Li, Kenzo Yahata
-
Patent number: 10633393Abstract: The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.Type: GrantFiled: August 26, 2019Date of Patent: April 28, 2020Assignee: Translational Drug DevelopmentInventors: Tong Wang, Stephen Gately
-
Patent number: 10633394Abstract: A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.Type: GrantFiled: November 30, 2015Date of Patent: April 28, 2020Assignee: C&C RESEARCH LABORATORIESInventors: Chan Hee Park, Sang Hwi Lee, Junhwan Im, Soon Ok Lee, Jungsook Kim, Heon Kyu Park, Jee Hun Yun, Kwang Seok Ko, Hye Jung Kim, Byungho Kim, Mi Sun Kim, Minjung Kong, Hyung Jo Moon
-
Patent number: 10633395Abstract: The invention relates to aryloxazolidinone compounds of formula I: wherein Y represents hydrogen or certain chemical groups. These compounds are useful antimicrobial agents effective against a variety of pathogens including inter alia Gram-negative aerobic and anaerobic bacteria.Type: GrantFiled: February 16, 2018Date of Patent: April 28, 2020Assignee: Idorsia Pharmaceuticals Ltd.Inventors: Daniel Ritz, Georg Rueedi, Cornelia Zumbrunn
-
Patent number: 10633396Abstract: The present invention claims UV detectable (?>210 nm) potassium [18F]fluoride diaryl- and aryl-fused [2.2.2]cryptate complexes suitable for performing radio-labeling reactions to generate [18F] fluorinated species.Type: GrantFiled: June 22, 2018Date of Patent: April 28, 2020Inventors: Yousry M. A. Naguib, Ashraf Naguib, Ahmed Naguib
-
Patent number: 10633397Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.Type: GrantFiled: December 17, 2018Date of Patent: April 28, 2020Assignee: SHIONOGI & CO., LTD.Inventor: Makoto Kawai
-
Patent number: 10633398Abstract: The disclosure provides an improved synthesis for a zinc-lysine complex having the formula [Zn(C6H14N2O2)2Cl]+Cl?, in which zinc chloride is reacted with lysine, in aqueous solution. The disclosure also provides oral care and personal care compositions comprising the complex prepared by the synthesis, and methods of using these complexes and compositions.Type: GrantFiled: June 18, 2014Date of Patent: April 28, 2020Assignee: Colgate-Palmolive CompanyInventors: Shiri Nawrocki, Ravi Subramanyam, Long Pan
-
Patent number: 10633399Abstract: Disclosed are functionalized aminobenzoboroxoles compounds, method for preparing these compounds, and methods for treating cancers.Type: GrantFiled: August 15, 2016Date of Patent: April 28, 2020Assignee: Channel Therapeutics, Inc.Inventors: Kandalam V. Ramanujachary, Subash C. Jonnalagadda
-
Patent number: 10633400Abstract: Nanocomposite silicon and carbon compositions. These compositions can be made from polymer derived ceramics, and in particular, polysilocarb precursors. The nanocomposite can have non-voids or be nano-void free and can form larger macro-structures and macro-composite structures. The nanocomposite can contain free carbon domains in an amorphous SiOC matrix.Type: GrantFiled: May 11, 2017Date of Patent: April 28, 2020Assignee: Melior Innovations, Inc.Inventors: Andrew R. Hopkins, Douglas M. Dukes, Brian L. Benac, Ashish P. Diwanji, Charles C. Rinzler, Mark S. Land
-
Patent number: 10633401Abstract: The invention relates to a process for preparing isocyanate containing alkoxysilane groups, in which, in the sequence of steps A) to D), A) alkoxysilano(cyclo)alkylamine is reacted with dialkyl carbonate in the presence of a basic catalyst to give alkoxysilano(cyclo)alkylurethane, B) simultaneously or successively, the catalyst is deactivated, and low boilers, solids, salt burdens and/or high boilers are removed, C) alkoxysilano(cyclo)alkylurethane obtained after B) is thermally cleaved to release isocyanate containing alkoxysilane groups and by-product, leaving bottoms material, and D) isocyanate containing alkoxysilane groups and by-product are separated from one another and from bottoms material and collected, wherein the process regime at least of steps C) to D) is continuous.Type: GrantFiled: March 15, 2019Date of Patent: April 28, 2020Assignee: Evonik Operations GmbHInventors: Manfred Kreczinski, Stephan Kohlstruk, Emmanouil Spyrou, Dirk Hoppe
-
Patent number: 10633402Abstract: A novel method and system for using certain tin compounds as dopant sources for ion implantation are provided. A suitable tin-containing dopant source material is selected based on certain attributes. Some of these attributes include stability at room temperature; sufficient vapor pressure to be delivered from its source supply to an ion chamber and, the ability to produce a suitable beam current for ion implantation to achieve the required implant Sn dosage.Type: GrantFiled: January 16, 2019Date of Patent: April 28, 2020Assignee: Praxair Technology, Inc.Inventors: Aaron Reinicker, Ashwini K. Sinha, Qiong Guo
-
Patent number: 10633403Abstract: Provided herein are N-heterocyclic phosphines (NHPs) useful in metal-free phosphorus-carbon bond forming reactions. Methods for preparing vinylphosphonates using NHPs also are provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: September 9, 2015Date of Patent: April 28, 2020Assignee: THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADAInventors: Jun Yong Kang, Karimulla Mulla, Kyle Aleshire, Paul M. Forster
-
Patent number: 10633404Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F18) radioisotope, or other radionuclide.Type: GrantFiled: March 10, 2016Date of Patent: April 28, 2020Assignee: Emory UniversityInventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
-
Patent number: 10633405Abstract: Provided is a method of coalescing a substance comprising providing a first mixture comprising a substance, agitating at least a portion of the first mixture under turbulent conditions for a first time period, thereby causing particles comprising and substance to collide and form into larger particles.Type: GrantFiled: March 25, 2019Date of Patent: April 28, 2020Assignee: Renmatix, Inc.Inventors: Patrick David Fitzgibbon, Thomas Arthur Kindler, Todd Michael McLarty, Charles Sebastian Sanderson, Michael L. Smith
-
Patent number: 10633406Abstract: Batch “water processes” for producing high functionality polyether polyols from polyhydroxyl compounds that are solid at ambient conditions, such as is the case with sucrose, are disclosed. The disclosed processes avoid use of an intermediate dewatering step.Type: GrantFiled: November 15, 2018Date of Patent: April 28, 2020Assignee: Covestro LLCInventors: Anthony R. Loveday, Daniel R. Wagner
-
Patent number: 10633407Abstract: Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macro-cyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.Type: GrantFiled: October 8, 2015Date of Patent: April 28, 2020Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
-
Patent number: 10633408Abstract: The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therapeutic agent.Type: GrantFiled: May 19, 2016Date of Patent: April 28, 2020Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Philippe Barthelemy, Khalid Oumzil
-
Patent number: 10633409Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.Type: GrantFiled: January 18, 2019Date of Patent: April 28, 2020Assignees: UNIVERSITE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Philippe Barthelemy, Michael Ramin, Laurent Latxague, Ananda Appavoo, Olivier Chassande, Camille Ehret
-
Patent number: 10633410Abstract: The present invention relates to methods of using optimized aptamers. In certain embodiments, the present invention provides a method for treating a subject having or being disposed to having a histone-induced injury or disease comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and (i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA; or (ii) a conjugate comprising a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA, wherein the nucleic acid molecule is linked to a therapeutic molecule.Type: GrantFiled: December 22, 2015Date of Patent: April 28, 2020Assignee: University of Iowa Research FoundationInventors: Paloma H. Giangrande, Francis Miller, Kevin Urak
-
Patent number: 10633411Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.Type: GrantFiled: November 18, 2019Date of Patent: April 28, 2020Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
-
Patent number: 10633412Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.Type: GrantFiled: July 31, 2018Date of Patent: April 28, 2020Assignee: Allergan Sales, LLCInventors: Achampeta Rathan Prasad, Roy A. Swaringen, Jr., John Gregory Reid, Robert M. Moriarty, Akhila Kumar Sahoo
-
Patent number: 10633413Abstract: This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminosterol, such as squalamine, a naturally occurring aminosterol isolated from Squalus acanthias, or derivatives thereof, to a subject in need.Type: GrantFiled: July 13, 2018Date of Patent: April 28, 2020Assignee: ENTERIN, INC.Inventor: Michael Zasloff
-
Patent number: 10633414Abstract: Methods of refolding proteins are provided, especially cysteine-containing proteins such as insulin, proinsulin, and analogues thereof. The methods make used of tandem folding via the addition, at two different time, of two different reducing agents. A first reversible reducing agent can be added to induce folding and, at a later time, a second irreversible reducing agent can be added to prevent and/or reverse the formation of aggregates via intermolecular sulfide bonds. The methods can be used to reform a variety of cysteine-containing proteins with high yield of the native form, e.g. about 60 mol %, 70 mol %, or more.Type: GrantFiled: July 27, 2016Date of Patent: April 28, 2020Assignee: Purdue Research FoundationInventors: Nien-Hwa Linda Wang, Chongli Yuan, Morgan H. Crawford
-
Patent number: 10633415Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.Type: GrantFiled: March 7, 2016Date of Patent: April 28, 2020Assignee: STEALTH BIOTHERAPEUTICS CORPInventors: Scott Duncan, D. Travis Wilson
-
Patent number: 10633416Abstract: Disclosed are a conotoxin polypeptide ?-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence SLCCPEDRWCC (SEQ. ID NO. 1).Type: GrantFiled: September 30, 2014Date of Patent: April 28, 2020Assignee: BGI Shenzhen Co., LtdInventors: Zhilong Lin, Bo Wen, Ting Tong, Jie Liu, Chaoqin Du, Fen Mo, Chao Peng, Qiong Shi
-
Patent number: 10633417Abstract: The present disclosure describes analog conotoxin peptides of the ?-contoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.Type: GrantFiled: May 30, 2014Date of Patent: April 28, 2020Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventor: J. Michael McIntosh
-
Patent number: 10633418Abstract: The purpose of the present invention is to provide a cross-linked peptide containing a novel non-peptide cross-linked structure, and a method for synthesizing the same. A cross-linked peptide having a novel non-peptide cross-linked structure, a useful intermediate for synthesizing the cross-linked peptide, and a method for synthesizing the novel cross-linked peptide and the intermediate are provided. The cross-linked peptide is characterized by having an —NR— bond in the cross-linked structure. By using the method for synthesizing the cross-linked peptide, a cross-link can be freely designed and an change can be freely made to a cross-link.Type: GrantFiled: May 17, 2016Date of Patent: April 28, 2020Assignee: JITSUBO CO., LTD.Inventors: Yusuke Kono, Shuji Fujita, Hideaki Suzuki, Mari Okumoto, Takashi Nakae, Kazuhiro Chiba
-
Patent number: 10633419Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: November 27, 2017Date of Patent: April 28, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: 10633420Abstract: Peptides having antimicrobial properties are described herein, as are compositions containing such peptides, and methods for using the peptides.Type: GrantFiled: July 27, 2017Date of Patent: April 28, 2020Assignee: GEORGE MASON RESEARCH FOUNDATION, INC.Inventors: Barney Bishop, Monique van Hoek, Ezra Myung Chul Chung
-
Patent number: 10633421Abstract: The present description relates to synthetic peptides useful for increasing the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells. More specifically, the present description relates to synthetic peptides and polypeptide-based shuttle agents comprising an endosome leakage domain (ELD) operably linked to a cell penetrating domain (CPD), or an ELD operably linked to a histidine-rich domain and a CPD. Compositions, kits, methods and uses relating to same are also described.Type: GrantFiled: April 12, 2017Date of Patent: April 28, 2020Assignee: Feldan Bio Inc.Inventors: David Guay, Thomas Del'Guidice, Jean-Pascal Lepetit-Stoffaes
-
Patent number: 10633422Abstract: A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.Type: GrantFiled: June 1, 2016Date of Patent: April 28, 2020Assignee: Wisconsin Alumni Research Foundation (WARF)Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping
-
Patent number: 10633423Abstract: The present disclosure relates to complex comprising an engineered polypeptide having affinity for interleukin-6 (in the following referred to as IL-6) and an antibody or an antigen binding fragment thereof, wherein said engineered polypeptide having affinity for IL-6 belongs to a class of engineered polypeptides comprising the sequence EEX3X4AWX7EIHX11 LPN-LX16X17X18QX20X21AFIX25X26LX28X29. The present disclosure also relates to the use of said complex as a therapeutic agent.Type: GrantFiled: June 15, 2015Date of Patent: April 28, 2020Assignees: AFFIBODY AB, ABCLON, INC.Inventors: Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 10633424Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: February 14, 2018Date of Patent: April 28, 2020Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 10633425Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.Type: GrantFiled: July 3, 2018Date of Patent: April 28, 2020Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
-
Patent number: 10633426Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.Type: GrantFiled: June 5, 2017Date of Patent: April 28, 2020Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
-
Patent number: 10633427Abstract: The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.Type: GrantFiled: June 24, 2016Date of Patent: April 28, 2020Assignee: PRINDEX S.R.L.Inventors: Roberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone
-
Patent number: 10633428Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.Type: GrantFiled: August 19, 2016Date of Patent: April 28, 2020Assignee: ALBUMEDIX LTDInventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
-
Patent number: 10633429Abstract: A human antibody ? type light chain complex-containing composition includes a complex in which a human antibody ? type light chain is bound to one or more kinds of metal ions selected from the group consisting of Group 10 elements, Group 11 elements, and Group 12 elements. The human antibody ? type light chain is a dimer, cysteines at C terminals of two human antibody ? type light chains are bound to each other via the metal ion, and 0.1 mol or more of the metal ion is bound per 1 mol of the human antibody ? type light chain.Type: GrantFiled: August 13, 2014Date of Patent: April 28, 2020Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Taizo Uda, Emi Hifumi
-
Patent number: 10633430Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions 47-49 and any one of positions 67-71, based on Kabat numbering; in one example, the Cys may be introduced at positions 49 and 69, based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions 62-66, based on Kabat numbering; in one example, the Cys residues may be introduced at positions 48 and 64, based on Kabat numbering.Type: GrantFiled: June 10, 2016Date of Patent: April 28, 2020Assignee: National Research Council of CanadaInventors: Dae Young Kim, Jamshid Tanha
-
Patent number: 10633431Abstract: The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies—RYB1, RYB2 and RYB3—and of a composition based thereon for the prevention and treatment of hepatitis C. Said antibodies are produced by cultivation using hybrid BIONA-RYB1, BIONA-RYB2 and BIONA-RYB3. The effectiveness of the antibodies is due to said antibodies binding epitopes, namely Ep1, Ep2 and Ep3 of E2 protein of the hepatitis C viral envelope, respectively. The present invention has demonstrated a neutralizing activity of the antibodies in a model system of infection of human cells in a culture. It has been shown that use of the claimed group of inventions provides for more reliable antibody binding of the hepatitis C virus.Type: GrantFiled: August 29, 2014Date of Patent: April 28, 2020Inventors: Tatiana Nikolaevna Vlasik, Armen Sergeevich Sadgyan, Igor Nikolaevich Rybalkin, Alexandr Yasenovich Shevelev
-
Patent number: 10633432Abstract: The present invention relates to a VC-CAR molecule and a use thereof in removing HIV-1 infected cells. The VC-CAR molecule is characterized by linking an HIV-1 broad-spectrum neutralizing antibody VRC01 sourced scFv sequence and an intracellular domain sequence of a conventional CAR molecule which are respectively used as extracellular and intracellular domains. A T cell modified by the VC-CAR molecule can be specifically activated and secrete a great number of cytotoxicity-related cytokines, so that lysis of a target cell can be powerfully mediated, and it can be better used for anti-infection adoptive immunotherapy.Type: GrantFiled: January 23, 2017Date of Patent: April 28, 2020Assignee: Shenzhen City of Regeneration Biological Pharmaceutical Technology Co., Ltd.Inventors: Hui Zhang, Bingfeng Liu, Fan Zou
-
Patent number: 10633433Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: July 2, 2016Date of Patent: April 28, 2020Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORKInventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Patent number: 10633434Abstract: The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.Type: GrantFiled: June 13, 2017Date of Patent: April 28, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Hu, Adrianna Latuszek, Carmelo Romano, William Olson
-
Patent number: 10633435Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.Type: GrantFiled: March 4, 2019Date of Patent: April 28, 2020Assignee: JANSSEN PHARMACEUTICA NVInventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo
-
Patent number: 10633436Abstract: The invention provides anti-Tau antibodies and methods of using the same.Type: GrantFiled: May 7, 2019Date of Patent: April 28, 2020Assignees: Genentech, Inc., AC Immune SAInventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
-
Patent number: 10633437Abstract: Disclosed herein is a method of treating a patient suffering a myocardial infarction, particularly an acute myocardial infarction, or of reducing an adverse consequence of a myocardial infarction in a patient comprising administering an antagonist of TGF-? to the patient during the acute stage of the myocardial infarction.Type: GrantFiled: December 12, 2016Date of Patent: April 28, 2020Assignee: GENZYME CORPORATIONInventors: Geoffrey Y. Akita, Scott Lonning, Richard C Gregory, Jr., Amelia B Kudej
-
Patent number: 10633438Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.Type: GrantFiled: September 22, 2016Date of Patent: April 28, 2020Assignee: VHsquared LimitedInventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray
-
Patent number: 10633439Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.Type: GrantFiled: February 26, 2019Date of Patent: April 28, 2020Assignees: MORPHOSYS AG, GALAPAGOS NVInventors: Jan Dominik Haas, Jürgen Klattig, Nick Ernest Rene Vandeghinste